

MARKET DATA

Symbol	822.1 HK
Exchange	HKSE
Share Price	\$0.43
Shares Outstanding	N/A
Market Cap:	\$177.64M

RECENT DEVELOPMENTS

Market focused development

Expansion via licensing with over 19 products under registration

Building intellectual property portfolio

Established network of opinion leaders in multi-discipline areas

Expansion through cooperation

Wholly-owned subsidiary located in China, comprising 3 GMP-compliant workshops of opical gel, lyophilized powder for injection, small volume parenteral solutions and eye gel

Five Professionals fully devoted to dossier translation and preparation

A clinical development team composed of 15 professionals with 4 trained physicians


Extensive network covering every province in the PRC with 500 partnerships

Regional offices in Beijing, Shanghai and Guangzhou



Lee's Pharmaceutical Holdings Limited

Unit 110-111, Bio-Informatics Centre
No. 2 Science Park West Avenue
HK Science Park, Shatin, Hong Kong
(852) 2314 1282
www.leespharm.com



Benjamin Li, MD. PhD.
Chief Executive Officer

PRODUCT AND PRODUCT CANDIDATE PIPELINE

Product: Livaracine®
Generic name: MWH
Medical Application: Cardiovascular Diseases
Year: 1998

Product: Yallaferon®
Generic name: Interferon
Medical Application: Venereal Diseases
Year: 2001

Product: Carnitene®
Generic name: L-Carnitine
Medical Application: Cardiac Diseases
Year: 2003

Product: Slounase®
Generic name: Hemocoagulase
Medical Application: Reduction of Bleeding
Year: 2006

Product: Ferplex®
Generic name: Iron P.S.
Medical Application: Sideropenic Anaemias
Year: 2007

Company Description

Lee's Pharmaceutical Holdings Limited (Lee's Pharm or "the Group") is a public biopharmaceutical company with over 13 years operation in China. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales & marketing in China. Lee's Pharm focuses on several areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology & others. It has more than 15 products under different development stages stemming from internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies.

Sigma Tau Group, the leading international pharmaceutical company based in Rome (Italy), is a strategic shareholder of Lee's Pharm. Sigma Tau's ongoing R&D activities and commercial know-how will result in creating significant business synergies for Lee's Pharm.